Description

BPC-157 Capsules 500MCG

We provide BPC-157 Capsules as an oral-format research presentation containing 500MCG per capsule, 180 capsules per container, and a stated 99.1% purity. Furthermore, BPC-157 is a synthetic 15-amino-acid pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). Consequently, researchers have investigated the compound across gastrointestinal biology, angiogenic signaling, nitric oxide pathways, vascular responses, and musculoskeletal tissue research.

Key Attributes

• Brand: AvigenLab
• Product Name: BPC-157 Capsules
• Active Compound: BPC-157
• Quantity: 180 Capsules
• Amount Per Capsule: 500MCG
• Stated Purity: 99.1%
• Molecular Type: Synthetic Pentadecapeptide
• Sequence: GEPPPGKPADDAGLV
• Sequence Length: 15 Amino Acids
• Molecular Weight: 1,419.5 g/mol
• Product Format: Capsules
• Classification: Research Use Only
• Human Use: Not For Human Use

BPC-157 Capsules Product Overview

We provide BPC-157 Capsules as a defined capsule-format research product designed around the BPC-157 pentadecapeptide. Moreover, the compound has attracted extensive preclinical research interest because investigators have examined its relationship with VEGFR2 signaling, FAK-paxillin activity, Egr-1 expression, nitric oxide regulation, and other cellular pathways.

Additionally, BPC-157 has a well-established research history involving gastrointestinal and tissue biology. Studies have investigated the peptide in experimental models involving intestinal tissue, vascular structures, connective tissue, tendon, ligament, and muscle. Therefore, the compound provides researchers with a broad molecular model for examining interactions between peptide signaling and tissue-response pathways.

Researchers can explore additional materials through our Online Store.

BPC-157 Capsules Product Identification

We identify BPC-157 Capsules through their defined 500MCG-per-capsule configuration, 180-capsule quantity, and stated 99.1% purity. Furthermore, BPC-157 has a clearly established molecular sequence of GEPPPGKPADDAGLV and a molecular weight of approximately 1,419.5 g/mol.

Accordingly, the product name, capsule quantity, active-compound amount, purity designation, molecular sequence, and research classification provide clear reference points for laboratory inventory and documentation.

Product Category

We classify BPC-157 Capsules within our research peptide collection, particularly within materials relevant to gastrointestinal, vascular, regenerative, and musculoskeletal research. Accordingly, the product connects a defined peptide identity with a convenient capsule-based research configuration.

Moreover, published literature describes BPC-157 as a stable gastric pentadecapeptide and examines its activity across multiple biological systems. Consequently, researchers can investigate the compound through several interconnected areas rather than limiting research to one proposed mechanism.

Scientific Characteristics

BPC-157 contains 15 amino acids arranged as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. In particular, PubChem lists its molecular formula as C₆₂H₉₈N₁₆O₂₂ and its molecular weight as 1,419.5 g/mol.

Furthermore, current research has identified several proposed molecular targets and signaling pathways associated with BPC-157. These include VEGFR2, the Egr-1 transcriptional pathway, the nitric oxide system, and FAK-paxillin signaling. Meanwhile, researchers continue examining how these pathways interact across different experimental models.

Research Applications

We position BPC-157 Capsules for research involving angiogenic signaling, gastrointestinal biology, vascular responses, nitric oxide pathways, connective-tissue biology, and musculoskeletal research.

Additionally, experimental studies have investigated BPC-157 in relation to VEGFR2 activation, endothelial signaling, angiogenesis, fibroblast activity, and extracellular-matrix responses. As a result, the compound has developed a substantial preclinical research profile involving tissue and vascular biology.

Likewise, researchers have investigated interactions between BPC-157 and the nitric oxide system. Studies have examined pathways involving eNOS, VEGFR2-Akt-eNOS signaling, and related vascular responses. Nevertheless, these findings primarily come from experimental models, so researchers should evaluate individual results according to the specific model and methodology used.

Product Configuration

We provide BPC-157 Capsules in a container holding 180 capsules, with each capsule labeled at 500MCG. Accordingly, the presentation provides a total labeled peptide quantity of 90MG across the full 180-capsule count.

Furthermore, the capsule configuration distinguishes this product from our spray-based BPC-157 presentation. Therefore, researchers can clearly differentiate the products through their dosage-unit format, quantity, and physical presentation.

Product Features

The primary features of BPC-157 Capsules include 500MCG per capsule, 180 capsules per container, a stated 99.1% purity, and a defined 15-amino-acid peptide identity. Additionally, the product label communicates Research Use Only and Not For Human Use.

Moreover, the research profile of BPC-157 encompasses several interconnected biological pathways. Researchers have examined angiogenesis, vascular signaling, gastrointestinal responses, nitric oxide regulation, and connective-tissue mechanisms. Consequently, the material offers a defined peptide subject for multidisciplinary laboratory investigation.

Product Specifications

The molecular sequence and molecular weight correspond with the chemical identity documented by PubChem.

Intended Research Context

We identify BPC-157 Capsules as Research Use Only and Not For Human Use. Accordingly, our product documentation focuses on laboratory research rather than therapeutic or consumer applications.

In particular, researchers can investigate the compound within experimental systems involving gastrointestinal signaling, vascular biology, angiogenic pathways, connective-tissue responses, and nitric oxide regulation. Furthermore, research literature has examined BPC-157 through oral, intragastric, and other experimental administration routes, although route-specific findings require careful interpretation.

Nevertheless, preclinical findings should not automatically translate into established human outcomes. Therefore, our documentation distinguishes scientific research observations from clinical or therapeutic claims.

Packaging Information

We present BPC-157 Capsules in a clearly labeled container holding 180 capsules. The product presentation identifies BPC-157, communicates 500MCG per 1 capsule, displays the stated 99.1% Purity, and identifies the material as Research Use Only.

Additionally, the capsule format provides straightforward product identification within our research catalog. Consequently, researchers can distinguish this presentation from liquid, vial-based, or spray-format BPC-157 products.

Regulatory Information

We classify the product as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, scientific publications concerning BPC-157 do not constitute regulatory approval for this specific AvigenLab product presentation.

Moreover, current literature continues to identify important translational questions surrounding BPC-157, including formulation, pharmacokinetics, administration routes, and human research. Consequently, we document the compound according to its established molecular characteristics and research literature without presenting experimental observations as established clinical outcomes.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Because peptide stability can depend on formulation, capsule composition, packaging, environmental exposure, and other product-specific factors, we avoid assigning unsupported storage parameters.

Furthermore, researchers should maintain appropriate laboratory handling practices and follow the product-specific documentation associated with the material. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our BPC-157 Capsules provide a defined capsule-format research configuration containing 500MCG per capsule and 180 capsules per container. The product name, quantity, purity designation, molecular identity, capsule format, and Research Use Only classification create clear reference points for laboratory inventory.

Moreover, BPC-157 maintains an extensive preclinical research history involving gastrointestinal, vascular, musculoskeletal, and tissue-response studies. Likewise, continued investigation into VEGFR2, nitric oxide, Egr-1, and related pathways keeps the peptide relevant to contemporary experimental biology.

Product Reference

Our BPC-157 Capsules provide a defined 500MCG-per-capsule research presentation containing 180 capsules and carrying a stated 99.1% purity designation. We document the material according to its GEPPPGKPADDAGLV sequence, molecular characteristics, capsule configuration, research applications, and Research Use Only status.

Consequently, the product provides researchers with a clearly identified material for investigating angiogenic signaling, gastrointestinal biology, nitric oxide pathways, vascular responses, and musculoskeletal tissue mechanisms. Furthermore, ongoing research continues to examine the interconnected signaling pathways associated with BPC-157 while researchers work to clarify its pharmacological and translational characteristics.